SECONDARY PROPHYLAXIS OF CERVICAL CANCER

The article reviews contemporary approaches to secondary prophylaxis of cervical cancer and emphasizes the role of early diagnostics of cervical cancer implemented in form of screening programs. The role of HPV testing in terms of screening program is also reviewed. According to analyzed data the crucial actions to perform a successful screening program are: determination of correct target group, choice of appropriate screening method and economic feasibility. Thus in majority of countries it is recommended to start screening at the age of 25-30 years while screening in younger age is clinically and economically unpractical. The results of clinical studies also shows that annual screening is ineffective and economically inappropriate, it is recommended to recall patients with negative results in 3-5 years depending on the method that was used. The choice of screening method is widely discussed. The vast majority of metaanalyses and reviews acknowledge high relevance of HPV testing in screening program. At the moment there are different approaches in utilization of HPV test. It may be used either in primary screening (along with cytology or as the only primary screening test), or as triage test for patients with doubtful cytology or colposcopy results. More of it at present moment there is a significant amount of data on effectiveness of HPV testing as a test-of-cure.

рак шейки матки, вирус папилломы человека, ПАП-тест, скрининг рака шейки матки, цитология, cervical cancer, human papilloma virus, PAP-test, cervical cancer screening, cytology

1. Comprehensive Control of HPV Infections and Related Diseases 20 November 2012 / Ed. by F.X. Bosch, T.R. Broker, M. Schiffman, J. Cuzick, C.J.L.M. Meijer, R. Sankaranarayanan, X. Castellsagué, J.J. Kim, M.A. Kane, M. Steben, L.A. Denny, M. Brotons and S. de Sanjosé // 2012. - 20 Nov. - Vol. 30. - Suppl. 5. - P. F1-F202.

2. Роговская С.И., Полонская Н.Ю. Профилактика рака шейки матки. Современные стратегии // Глава в кн. Шейка матки, влагалище, вульва,под ред. Роговской СИ, Лииповой ЕВ. - 2016. -С. 824-847.

3. Slade B.A., Leidel L., Vellozzi C. et al. Human Papillomavirus Recombinant Vaccine Postlicensure // JAMA. - 2009. - Vol. 302 (7). - P. 750-757. [doi:10.1001/ Jama.2009.1201.]

4. Einstein M.et al. // Human vaccines. - 2009. - Oct. - Vol. 5. - Issue 10. - P. 702-716.

5. Профилактика рака шейки матки: Руководство для врачей / Г.Т. Сухих, В.Н. Прилепская, Т.Н. Бебнева и др. - М.: МЕДпресс-информ, 2012. - 192 с.

6. Новик В.И. Скрининг рака шейки матки // Практическая онкология. - 2010. - №11 (2). - С. 66-73.

7. Anttila A., Karsab L. von, Aasmaac A. et al. Cervical cancer screening policies and coverage in Europe // Eur. J. Cancer. - 2009. - Vol. 45. - P. 2649-2658.

8. Arbyn M., Anttila A., Jordan J. et al. (ed.) European guidelines for quality assurance in cervical cancer screening. - 2nd ed. - Luxembourg: Office for Official Publications of the European Communities, 2008.

9. Sanner et al. Self-sampling of the vaginal fluid at home combined with high-risk HPV testing // British J. of Cancer. -2009. -Vol. 101. -P. 871-74.

10. Комплексная борьба с раком шейки матки: Краткое практическое руководство. - Всемирная организация здравоохранения, 2010. - 278 с. - URL: http://www.who.int/reproductive#health/publications/cervical.

11. Полонская Н.Ю., Шабалова И.П. Цитологическая диагностика. - М., 2009.

12. Dallenbach-Hellweg G.,Trunk M.J., Von Knebel Doeberitz M. Traditional and new molecular methods for early detection of cervical cancer // Arch. Pathol. - 2004. - №5. -P. 35-39.

13. Bosch F.X., De Sanjose S. Chapter 1: Human papillomavirus and cervical cancer burden // Vaccine Monogr. - 2012. - Vol. 31. - P. 3-13.

14. Rogovskaya S.I., Shabalova I.P., Mikheeva I.V., Minkina G.N., Podzolkova N.M., Shipulina O.Y., Sultanov S.N., Kosenko I.A., Brotons M., Buttmann N., Dartell M., Arbyn M., Syrjanenl S., Poljak M. Human Papillomavirus Prevalence and Type-Distribution, Cervical Cancer Screening Practices and Current Status of Vaccination Implementation in Russia, the Western Countries of the former Soviet Union, Caucasus Region and Central Asia ICO/WHO Monograph // J. Vaccine. -2013. - Dec. -Vol. 31- Suppl. 7. - P. H46-58. [doi: 10.1016/j.vaccine.2013.06.043.]

15. Souayah N., Michas-Martin P.A., Nasar A., Krivitskaya N., Yacoub H. Khan A.H., Qureshi A.I. Guillain-Barr syndrome after Gardasil vaccination: Data from Vaccine Adverse Event Reporting System 2006-2009 // Vaccine. - 2011. - Vol. 29. -P. 886-889.

16. International Agency for Research on Cancer. IARC/WHO handbooks of cancer prevention: cervix cancer screening. - Vol. 10. - Lyon: IARC Press, 2005. - P. 1-302.

17. Saslow D., Solomon D., Lawson H.W., Killackey M., Kulasingam S.L., Cain J., Garcia .FA., Moriarty A.T., Waxman A.G., Wilbur D.C., Wentzensen N., Downs L.S.Jr., Spitzer M., Moscicki A.B., Franco E.L., Stoler M.H., Schiffman M., Castle P.E., Myers E.R. ACS-ASCCP-ASCP Cervical Cancer Guideline Committee. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer // CA Cancer J. Clin. -2012. -Vol. 62. -P. 147-72.

18. Расследование поствакцинальных осложнений. МУ 3.3.1879-04. - М., - 13 с.

19. Коломиец Л. А., Чуруксаева О. Н., Уразова Л. Н., Чернышова А. Л., Молчанов С. В., Мунтян А. Б., Замкова О. В., Видяева И. Г. Вакцинация против ВПЧ - первичная профилактика рака шейки матки. Томск: Изд-во «Печатная мануфактура», 2011. 116 с

20. Grace A., McBrearty P., Troost S., Thornhill M., Kay E., Leader M. Comparative study: conventional cervical and ThinPrep Pap tests in routine clinical setting // Cytopatology. -2002. -ol. 13 (4). -P. 200-05.

21. Akker-van Marle M.E. van den, Ballegooijen M. van, Oortmarssen G.J. van, Boer R., Dik F.J. Habbema Cost Effectiveness of Cervical Cancer Screening: Comparison of Screening Policies. - 2002.

22. WHO Human papillomavirus (HPV) vaccine, Background paper, September 2008. - Geneva. - URL: http://www.who.int/immunization/documents/positionpapers/en/index.html. [accessed 24 March 2009.]

23. Kim T., Wright C., Sue J. Goldie Cost-effectiveness of Human Papillomavirus DNA Testing in J.J. the United Kingdom, The Netherlands, France, and Italy JNCI // J. of the National Cancer Institute. - 2005. - Vol. 97 (12). - P. 888-895. [doi:10.1093/jnci/dji162.]